EP3415501B1 - Chinolinderivat - Google Patents

Chinolinderivat Download PDF

Info

Publication number
EP3415501B1
EP3415501B1 EP18185739.2A EP18185739A EP3415501B1 EP 3415501 B1 EP3415501 B1 EP 3415501B1 EP 18185739 A EP18185739 A EP 18185739A EP 3415501 B1 EP3415501 B1 EP 3415501B1
Authority
EP
European Patent Office
Prior art keywords
group
oxy
dioxo
hexahydro
quinolinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18185739.2A
Other languages
English (en)
French (fr)
Other versions
EP3415501B9 (de
EP3415501A1 (de
Inventor
Takayuki Inukai
Jun Takeuchi
Tomoko YASUHIRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of EP3415501A1 publication Critical patent/EP3415501A1/de
Application granted granted Critical
Publication of EP3415501B1 publication Critical patent/EP3415501B1/de
Publication of EP3415501B9 publication Critical patent/EP3415501B9/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a compound represented by general formula (I): wherein all of the symbols have the same meanings as given below, a salt thereof, a solvate thereof, or an N-oxide thereof (hereinafter, also abbreviated as the compound of the present invention).
  • Axl (also known as: UFO, ARK, Tyro7) is a receptor tyrosine kinase belonging to a TAM family (Axl, Mer and Tyro3) cloned from tumor cells.
  • Gas6 growth-arrest-specific protein 6
  • Axl activated by binding of Gas6 transfers a signal via phosphorylation. Since the signal activates an Erk1/2 pathway or a PI3K/Akt pathway, the activation of Axl is known to be involved in pathologic conditions of cancers, immune system diseases, circulatory system diseases, and the like (see, Non-Patent Literature 1).
  • Axl the relation between Axl and various types of cancers is well known.
  • the expression of Axl is involved in metastasis and prognosis of breast cancer (see, Non-Patent Literature 2), and that Axl is involved in the pathologic conditions of acute myeloid leukemia (AML) (see Non-Patent Literature 3). Therefore, it is considered that compounds which inhibit the activation of Axl are useful for treatment of various type of cancers, immune system diseases, and circulatory system diseases.
  • R 1A , R 4A , and R 88A are independently -H, -F, -Cl, -Br, -I, -OH, -NH 2 , -OCH 3 , -OC 2 H 5 , or the like;
  • R 2A and R 3A are independently -R 88A or the like;
  • R 5A and R 6A may be the same as each other or different from each other, and represent -H, -F, -Cl, -Br, -I, -CN, -NO 2 , -CH 3 , or the like;
  • R 7A , R 8A , R 10A , and R 11A may be the same as each other or different from each other, and represent -H, -F, -Cl, -Br, -I, -CN, -NO 2 , -CH 3 , or the like;
  • R 9A represents -H or the like;
  • R 12A represents -
  • X B represents N or C-R 4B ;
  • Y B represents N or C-R 1dB ;
  • D B represents -O-, -S-, -NH- or the like;
  • W B represents CH or N;
  • R aB , R bB , R cB , R dB , R 1aB , R 1cB , R 1dB and R 4B independently represent a hydrogen atom, -OR 110B , or the like;
  • R 19B represents a halogen atom, -CN, or the like;
  • R 110B represents a hydrogen atom, a CI-6 alkyl group optionally substituted with one to six R 129
  • a compound having a quinoline skeleton and represented by the following general formula (C): is known to have an ASK1 inhibitory activity, and be an agent for preventing and/or treating amyotrophic lateral sclerosis (ALS) (see Patent Literature 3).
  • ALS amyotrophic lateral sclerosis
  • Patent Literature 6 discloses methods for treating cancer comprising administering to a patient therapeutically effective amounts of:
  • a problem to be solved by the present invention is to find a compound having an Axl inhibitory activity, which is useful for treatment of cancer such as AML, and to provide the compound as pharmaceuticals whose side effects are reduced.
  • the inventors of the present invention have keenly studied to find a compound strongly inhibiting Axl.
  • the inventors have found that a bicyclic structure, in which a saturated carbon ring is fused to a pyridone ring, represented by the following structural formula: improves the Axl inhibitory activity, and have completed the present invention.
  • the present invention relates to:
  • a compound of the present invention has a strong Axl inhibitory activity, has an Axl-selective inhibitory activity to a specific kinase, and has reduced CYP inhibitory effect, and therefore is useful as a therapeutic drug for acute myeloid leukemia, has less side effect and has little concern about drug interaction.
  • a halogen atom denotes a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • the C1-8 alkyl group includes a straight or branched C1-8 alkyl group.
  • Examples thereof include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, isobutyl, sec-butyl, tert-butyl, and an isomer thereof.
  • the C1-4 alkyl group includes a straight or branched C1-4 alkyl group. Examples thereof include methyl, ethyl, propyl, butyl, isopropyl, isobutyl, sec-butyl, and tert-butyl.
  • the C1-3 alkyl group includes a straight or branched C1-3 alkyl group. Examples thereof include a methyl group, an ethyl group, a propyl group, and an isopropyl.
  • the C1-4 haloalkyl group denotes, for example, a fluoromethyl group, a chloromethyl group, a bromomethyl group, an iodomethyl group, a difluoromethyl group, a trifluoromethyl group, a 1-fluoroethyl group, a 2-fluoroethyl group, a 2-chloroethyl group, a pentafluoroethyl group, a 1-fluoropropyl group, a 2-chloropropyl group, a 3-fluoropropyl group, a 3-chloropropyl group, a 4,4,4-trifluorobutyl group, and a 4-bromobutyl group.
  • the C2-8 alkenyl group denotes, for example, a vinyl group, a propenyl group, a butenyl group, a pentenyl group, a hexenyl group, a heptenyl group, and a octenyl group, and an isomer thereof.
  • the C2-8 alkynyl group denotes, for example, an ethynyl group, a propynyl group, a butynyl group, a pentynyl group, a hexynyl group, a heptynyl group, an octynyl group, and an isomer thereof.
  • examples of the C1-4 alkoxy group include a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group, a sec-butoxy group, or a tert-butoxy group.
  • the C2-4 alkenyloxy group denotes, for example, vinyloxy, propenyloxy, butenyloxy, and an isomer thereof.
  • the C2-4 alkynyloxy group denotes, for example, ethynyloxy, propynyloxy, butynyloxy, and an isomer thereof.
  • the C3-7 carbon ring denotes a C3-7 monocyclic carbon ring, and a carbon ring which may be partially or completely saturated, and examples thereof include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclobutadiene, cyclopentadiene, cyclohexadiene, cycloheptadiene, or benzene ring.
  • the C5-7 carbon ring denotes a C5-7 monocyclic carbon ring, and a carbon ring which may be partially or completely saturated, and examples thereof include cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, cyclohexadiene, cycloheptadiene, or benzene ring.
  • examples of the saturated C3-7 carbon ring include cyclopropane, cyclobutane, cyclopentane, cyclohexane, and cycloheptane.
  • the 4- to 7-membered heterocycle denotes 4- to 7-membered monocyclic heterocycle, which includes one to five heteroatoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, and a part or all of which is saturated.
  • Example thereof include azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, oxetan, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydro
  • the 5- to 7-membered cyclic group denotes C5-7 carbon ring and 5- to 7-membered heterocycle.
  • the C5-7 carbon ring has the same meaning as defined above
  • the 5- to 7-membered heterocycle includes 5- to 7-membered unsaturated heterocycle and 5- to 7-membered saturated heterocycle.
  • Examples of 5- to 7-membered heterocycle include pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrooxepin
  • the 6-membered cyclic group denotes C6 carbon ring and 6-membered heterocycle.
  • examples thereof include cyclohexane, cyclohexene, cyclohexadiene, benzene, pyridine, pyrazine, pyrimidine, pyridazine, pyran, thiopyran, oxazine, oxadiazine, thiazine, thiadiazine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydropyran, tetrahydropyran, dihydrothiopyran, tetrahydrothiopyran,
  • n is one or more, and one of R 2 is necessarily an oxo group.
  • A is CH.
  • R 4 is a C1-4 alkoxy group or an - OR 41 group.
  • L is -O-, -NH-, or -C(O)-.
  • ring 1 is benzene or pyridine.
  • the compound represented by general formula (I) is a compound represented by general formula (I-1): (wherein all of the symbols have the same meanings as defined above).
  • two binding arms in the ring1 and ring1-1 are bound to a para position.
  • A is preferably CH, and R 4 is preferably a C1-4 alkoxy group or an -OR 41 group.
  • preferable compounds preferably include the compounds described in Examples, and the following (2) to (17) are more preferable: (2)N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl ⁇ -7,7-dimethyl-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, (3)N- ⁇ 5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl ⁇ -1-(2,2-dimethylpropyl)-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, (4) N-[5-( ⁇ 7-[3-(4-morpholinyl)propoxy]-4-quinolinyl ⁇ oxy)-2-pyridinyl]-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide
  • an alkyl group includes straight chain and branched chain groups.
  • all of geometrical isomers of double bonds, rings, and fused rings (E-, Z-, cis-, trans-isomers), optical isomers by the presence of an asymmetric carbon atom (R-, S- isomer, ⁇ -, ⁇ -configurations, enantiomers, diastereomers), optical active isomers having optical rotation property (D, L, d, 1-isomers), polar isomers according to chromatographic separation (more polar isomer, less polar isomer), equilibrium compound, rotamers, mixtures thereof at any rate, and racemic mixtures are included in the present invention.
  • the present invention also encompasses all isomers by tautomers.
  • optical isomer of the present invention is not only limited to an optical isomer having purity of 100%, but also may include other optical isomers having purity of less than 50%.
  • a symbol represents binding toward the back side of the plane of the paper (that is to say, the ⁇ -configuration), represents binding toward the front side of the plane of the paper (that is to say, the ⁇ -configuration), and represents ⁇ -configuration, ⁇ -configuration or an arbitrary mixture thereof.
  • a salt is preferably a water-soluble salt.
  • suitable salt include salts of an alkali metal (e.g., potassium, sodium), salts of an alkaline earth metal (e.g., calcium, magnesium), ammonium salts, or salts of a pharmaceutically acceptable organic amine (e.g., tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)aminomethane, lysine, arginine, N-methyl-D-glucamine), acid addition salts (inorganic acid salts (e.g., hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, nitrate), organic acid salts (e.g., acetate
  • the compound represented by general formula (I) and a salt thereof can be also converted into a solvate. It is preferable that the solvate is low-toxic and water-soluble.
  • a suitable solvate include solvates with water, or an alcoholic solvent (for example, ethanol).
  • the N-oxide of the compound represented by general formula (I) denotes compounds represented by general formula (I) in which a nitrogen atom is oxidized. Furthermore, the N-oxide of the compound represented by general formula (I) may be salts of alkali (earth) metal salt, ammonium salt, organic amine salt, and acid addition salt mentioned above.
  • the compound of the present invention can be produced by the well-known methods, for example, the method described in Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999 ), or methods described in Examples, with appropriate modification and in combination thereof.
  • the reaction 1 can be carried out by subjecting a compound represented by general formula (a) and a compound represented by general formula (II) to the aromatic nucleophilic substitution reaction.
  • the aromatic nucleophilic substitution reaction is well known, and is carried out, for example, in an organic solvent (e.g., chlorobenzene, N,N-dimethyl sulfoxide, N,N-dimethyl acetamide, N,N-dimethylformamide, chloroform, dichloromethane, diethyl ether, tetrahydrofuran, methyl t-butyl ether), in the presence or absence of a catalyst (e.g., 4-dimethylaminopyridine (DMAP)), and in the presence or absence of a base (e.g., sodium hydride, triethylamine, cesium carbonate), at 0 to 200°C.
  • a catalyst e.g., 4-dimethylaminopyridine (DMAP)
  • a base e.
  • the reaction 2 is carried out by reacting a compound represented by general formula (b) in an organic solvent (e.g., tetrahydrofuran), in the presence of a palladium catalyst (e.g., tris(dibenzylideneacetone)dipalladium(0) chloroform complex), in the presence of a base (e.g., lithium bis(trimethylsilyl)amide (LHMDS), pottasium bis(trimethylsilyl)amide (KHMDS), sodium bis(trimethylsilyl)amide (NaHMDS)), a phosphine compound (e.g., 2-dicyclohexylphosphino-2' ,6' -dimethoxybiphenyl (S-Phos), tri-tert-butylphosphine (P(t-Bu) 3 )) at 0 to 100°C, and then reacting by adding inorganic acid (e.g., hydrochloric acid, hydrobromic acid, hydrochloric acid,
  • the reaction 3 is carried out by a reaction of a compound represented by general formula (d) and a compound represented by general formula (III).
  • the reaction is well known, and, for example, can be carried out at 0 to 100°C in an organic solvent (e.g., N,N-dimethyl formamide), in the presence of a base (e.g., tert-butoxy potassium).
  • organic solvent e.g., N,N-dimethyl formamide
  • a base e.g., tert-butoxy potassium
  • the reaction 4 can be carried out by subjecting a compound represented by general formula (e) and a compound represented by general formula (IV) to addition reaction.
  • the reaction is well known, and, for example, can be carried out by reacting at 0 to 100°C in an alcohol solvent (e.g., methanol, ethanol).
  • the reaction 5 can be carried out by using and subjecting the compound represented by general formula (c) and the compound represented by general formula (f) to an amidation reaction.
  • the amidation reaction is well known, and examples thereof include:
  • reactions (1), (2), and (3) are desirably carried out under an inert gas (e.g., argon, nitrogen) atmosphere in anhydrous conditions.
  • an inert gas e.g., argon, nitrogen
  • a compound represented by general formula (b)' can be produced by the same method as in the above-mentioned reaction 1 using a compound represented by general formula (a)' and the compound represented by general formula (V).
  • the reaction 6 can be carried out by subjecting the compound represented by general formula (b)' to a reduction reaction of the nitro group.
  • the reduction reaction of a nitro group is well known, and can be carried out by, for example, the following method.
  • a deprotection reaction when a compound represented by each general formula includes a protective group, a deprotection reaction can be carried out if necessary.
  • the deprotection reaction of the protective group is known, and can be carried out by the methods mentioned below. Examples thereof include: (1) deprotection reactions by alkaline hydrolysis, (2) deprotection reaction in acidic conditions, (3) deprotection reaction by hydrogenolysis, (4) deprotection reaction of a silyl group, (5) deprotection reaction using metal, (6) deprotection reaction using a metal complex.
  • the deprotection reaction can be carried out by the method described in for example, T. W. Greene, Protective Groups in Organic Synthesis, Wiley, New York, 1999 .
  • Examples of a protective group for a hydroxyl group include a methyl group, a trityl group, a methoxymethyl (MOM) group, a 1-ethoxyethyl (EE) group, a methoxyethoxymethyl (MEM) group, a 2-tetrahydropyranyl (THP) group, a trimethylsilyl (TMS) group, a triethylsilyl (TES) group, a t-butyldimethylsilyl (TBDMS) group, a t-butyldiphenylsilyl (TBDPS) group, an acetyl (Ac) group, a pivaloyl group, a benzoyl group, a benzyl (Bn) group, a p-methoxybenzyl group, an allyloxycarbonyl (Alloc) group, and a 2,2,2-trichloroethoxycarbonyl (Troc) group.
  • MOM
  • Examples of a protective group for an amino group include a benzyloxycarbonyl group, a t-butoxycarbonyl group, an allyloxycarbonyl (Alloc) group, a 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc) group, a trifluoroacetyl group, a 9-fluororenylmethoxycarbonyl group, a benzyl (Bn) group, a p-methoxybenzyl group, a benzyloxymethyl (BOM) group, and a 2-(trimethylsilyl)ethoxymethyl (SEM) group.
  • a benzyloxycarbonyl group a t-butoxycarbonyl group
  • an allyloxycarbonyl (Alloc) group a 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc) group
  • a trifluoroacetyl group a 9-fluororen
  • the protective groups for a hydroxyl group and an amino group are not particularly limited to the above-described groups, and groups are included, in addition to the above-mentioned groups, as long as the groups can be detached easily and selectively.
  • groups are included, in addition to the above-mentioned groups, as long as the groups can be detached easily and selectively.
  • those described in Protective Groups in Organic Synthesis T. W. Greene, John Wiley & Sons Inc., 1999 ) may be used.
  • a solid-supported reagent which is supported on a high molecular polymer e.g., polystyrene, polyacrylamide, polypropylene, polyethylene glycol
  • a high molecular polymer e.g., polystyrene, polyacrylamide, polypropylene, polyethylene glycol
  • the reaction products can be purified by conventional purification methods, for example, by distillation at normal or reduced pressure, by high performance liquid chromatography using silica gel or magnesium silicate, thin layer chromatography, ion-exchange resin, scavenger resin, or column chromatography, washing, or recrystallization.
  • the purification may be done after each reaction or after several reactions.
  • the toxicity of the compound of the present invention is sufficiently low, and the compound can be safely used as pharmaceuticals.
  • the compound of the present invention has an Axl inhibitory activity, it can be used as an agent for preventing and/or treating an Axl-related disease in mammals, especially in human.
  • examples of the Axl-related diseases include cancer, kidney diseases, immune system disease, and circulatory system disease.
  • the cancer includes acute myeloid leukemia, chronic myeloid leukemia, acute lymphatic leukemia, melanoma, breast cancer, pancreatic cancer, glioma, esophageal adenocarcinoma, large intestine cancer, renal cell carcinoma, thyroid cancer, non-small cell lung cancer, prostate cancer, stomach cancer, liver cancer, uveal malignant melanoma, ovarian cancer, endometrial cancer, lymphoma, head and neck cancer, and sarcoma.
  • kidney diseases include glomerular nephritis, chronic nephritis, IgA nephritis, sequential (secondary) nephritis, nephrosis nephritis, acute renal failure, chronic renal failure, diabetic nephropathy, gouty nephropathy, interstitial nephritis, and nephropyelitis.
  • examples of the immune system disease include psoriasis, and rheumatoid arthritis.
  • examples of the circulatory system disease include atherosclerosis and thrombosis.
  • the compound of the present invention since the compound of the present invention has an Axl inhibitory activity, it can be used as a metastasis suppressing agent to cancer cell.
  • the compound of the present invention may be administered as a combination drug in combination with other drugs in order to accomplish the following purposes:
  • a combination drug of the compound of the present invention and other drugs may be administered in the form of a compounding agent including these components mixed into one formulation, or may be administered in separate formulations.
  • Administration as separate formulations includes simultaneous administration and administration at different times. In the administration at different times, the compound of the present invention may be administered before the other drug. Alternatively, the other drug may be administered before the compound of the present invention.
  • the method for the administration of these drugs may be the same as each other or different from each other.
  • the other drugs for supplementing and/or enhancing the preventive and/or therapeutic effect of the compound of the present invention against cancer include, for example, alkylating agents, antimetabolites, anticancer antibiotics, plant alkaloids, hormones, platinum compounds, anti-CD20 antibodies, anti-CD52 antibodies, anti-PD-1 antibodies, G-CSF formulations, acute promyelocytic leukemia differentiation-inducing agents, kinase inhibitors, topoisomerase inhibitors, aromatase inhibitors, and other anticancer drugs.
  • the other drug for supplementing and/or enhancing the preventive and/or therapeutic effect of the compound of the present invention against kidney diseases include, for example, steroids, immunosuppressants, angiotensin II antagonistic drugs, angiotensin-converting enzyme inhibitors, antiplatelet drugs, and anticoagulant drugs.
  • the other drugs for supplementing and/or enhancing the preventive and/or therapeutic effect of the compound of the present invention against immune system diseases include, for example, immunosuppressants, steroid, disease-modifying anti-rheumatic drugs, prostaglandins, prostaglandin synthase inhibitors, phosphodiesterase inhibitors, metalloprotease inhibitors, anti-cytokine protein formulations such as anti-TNF- ⁇ formulations, anti-IL-1 formulations, and anti-IL-6 formulation, cytokine inhibitors, and nonsteroidal anti-inflammatory agents.
  • the other drugs for supplementing and/or enhancing the preventive and/or therapeutic effect of the compound of the present invention against circulatory system diseases include antiplatelet drugs, angiotensin II antagonistic drugs, angiotensin-converting enzyme inhibitors, HMG-CoA reductase inhibitors, and thiazolidine derivatives.
  • alkylating agents examples include nitrogen mustard N-oxide hydrochloride, cyclophosphamide, ifosfamide, melphalan, thiotepa, carboquone, busulfan, nimustine hydrochloride, dacarbazine, ranimustine, carmustine, chlorambucil, bendamustine, and mechlorethamine.
  • antimetabolites examples include methotrexate, mercaptopurine, 6-mercaptopurine riboside, fluorouracil, tegafur, tegafur uracil, carmofur, doxifluridine, cytarabine, enocitabine, tegafur gimestat otastat potassium, gemcitabine hydrochloride, cytarabine ocfosfate, procarbazine hydrochloride, and hydroxycarbamide.
  • anticancer antibiotics examples include actinomycin D, mitomycin C, daunorubicin hydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride, neocarzinostatin, pirarubicin hydrochloride, epirubicin (hydrochloride), idarubicin hydrochloride, chromomycin A3, bleomycin (hydrochloride), peplomycin sulfate, therarubicin, zinostatin stimalamer, and gemtuzumab ozogamicin.
  • Examples of the plant formulations include vinblastine sulfate, vincristine sulfate, vindesine sulfate, irinotecan hydrochloride, etoposide, flutamide, vinorelbine tartrate, docetaxel hydrate, and paclitaxel.
  • hormones examples include estramustine phosphate sodium, mepitiostane, epitiostanol, goserelin acetate, fosfestrol (diethylstilbestrol phosphate), tamoxifen citrate, toremifene citrate, fadrozole hydrochloride hydrate, medroxyprogesterone acetate, bicalutamide, leuprorelin acetate, anastrozole, aminoglutethimide, androgen bicalutamide, and fulvestrant.
  • platinum compounds examples include carboplatin, cisplatin, nedaplatin, and oxaliplatin.
  • anti-CD20 antibodies examples include rituximab, ibritumomab, ibritumomab tiuxetan, and ocrelizumab.
  • anti-CD52 antibodies examples include alemtuzumab.
  • anti-PD-1 antibodies examples include nivolumab, and pembrolizumab.
  • G-CSF formulation examples include pegfilgrastim, filgrastim, lenograstim, and nartograstim.
  • Examples of the differentiation-inducing agent for acute promyelocytic leukemia include tamibarotene, tretinoin, and arsenic trioxide formulations.
  • kinase inhibitors examples include EGFR inhibitors including erlotinib hydrochloride, gefitinib, cetuximab, and panitumumab; HER2 inhibitors including lapatinib and trastuzumab; BCR-ABL inhibitors including imatinib, dasatinib, and nilotinib; multikinase inhibitors including sunitinib, vandetanib, crizotinib, and sorafenib.
  • EGFR inhibitors including erlotinib hydrochloride, gefitinib, cetuximab, and panitumumab
  • HER2 inhibitors including lapatinib and trastuzumab
  • BCR-ABL inhibitors including imatinib, dasatinib, and nilotinib
  • multikinase inhibitors including sunitinib, vandetanib, crizotinib, and sorafeni
  • topoisomerase inhibitor examples include topotecan, teniposide, irinotecan, and sobuzoxane.
  • aromatase inhibitor examples include exemestane.
  • Examples of the other anticancer agents include L-asparaginase, octreotide acetate, porfimer sodium, mitoxantrone acetate, aceglatone, ubenimex, eribulin mesilate, cladribine, krestin, bexarotene, denileukin diftitox, temozolomide, nelarabine, fludarabine, bevacizumab, pemetrexed, pentostatin, bortezomib, lenalidomide, and calcium folinate.
  • immunosuppressant examples include azathioprine, ascomycin, everolimus, salazosulfapyridine, cyclosporine, cyclophosphamide, sirolimus, tacrolimus, bucillamine, methotrexate, and leflunomide.
  • Examples of the steroid include amcinonide, hydrocortisone sodium succinate, prednisolone sodium succinate, methylprednisolone sodium succinate, ciclesonide, difluprednate, betamethasone propionate, dexamethasone, deflazacort, triamcinolone, triamcinolone acetonide, halcinonide, dexamethasone palmitate, hydrocortisone, flumetasone pivalate, prednisolone butylacetate, budesonide, prasterone sulfate, mometasone furoate, fluocinonide, fluocinolone acetonide, fludroxycortide, flunisolide, prednisolone, alclometasone propionate, clobetasol propionate, dexamethasone propionate, deprodone propionate, fluticasone propionate, beclometasone propionate
  • angiotensin II antagonistic drug examples include losartan, candesartan, valsartan, irbesartan, olmesartan, and telmisartan.
  • angiotensin-converting enzyme inhibitor examples include alacepril, imidapril hydrochloride, quinapril hydrochloride, temocapril hydrochloride, delapril hydrochloride, benazepril hydrochloride, captopril, trandolapril, perindopril erbumine, enalapril maleate, and lisinopril.
  • antiplatelet drugs examples include dipyridamole, and dilazep hydrochloride hydrate.
  • anticoagulant drugs examples include warfarin and heparin.
  • Examples of the disease-modifying anti-rheumatic drugs include D-penicillamine, actarit, auranofin, salazosulfapyridine, hydroxychloroquine, bucillamine, methotrexate, leflunomide, lobenzarit sodium, aurothioglucose, and sodium aurothiomalate.
  • Examples of the prostaglandins include PGE1 formulations (examples: alprostadil alfadex, alprostadil), PGI2 formulations (example: beraprost sodium), PG receptor agonists, and PG receptor antagonists.
  • Examples of the PG receptor include PGE receptors (EP1, EP2, EP3, and EP4), PGD receptors (DP, and CRTH2), PGF receptors (FP), PGI2 receptors (IP), and TX receptors (TP).
  • prostaglandin synthase inhibitor examples include salazosulfapyridine, mesalazine, olsalazine, 4-aminosalicylic acid, JTE-522, auranofin, carprofen, diphenpyramide, flunoxaprofen, flurbiprofen, indometacin, ketoprofen, lornoxicam, loxoprofen, meloxicam, oxaprozin, parsalmide, naproxen, piroxicam, piroxicam cinnamate, zaltoprofen, and pranoprofen.
  • Examples of the phosphodiesterase inhibitor include rolipram, cilomilast, Bay19-8004, NIK-616, roflumilast (BY-217), cipamfylline (BRL-61063), atizoram (CP-80633), ONO-6126, SCH-351591, YM-976, V-11294A, PD-168787, D-4396, and IC-485.
  • anti-TNF- ⁇ formulation examples include anti-TNF- ⁇ antibodies, soluble TNF- ⁇ receptor, anti-TNF- ⁇ receptor antibodies, and soluble TNF- ⁇ binding protein, and particularly infliximab and etanercept.
  • anti-IL-1 formulation examples include anti-IL-1 antibodies, soluble IL-1 receptor, anti-IL-1Ra antibodies and/or anti-IL-1 receptor antibodies and particularly anakinra.
  • anti-IL-6 formulation examples include anti-IL-1 antibodies, soluble IL-6 receptor, and anti-IL-6 receptor antibodies, and particularly tocilizumab.
  • cytokine inhibitor examples include suplatast tosylate, T-614, SR-31747, and sonatimod.
  • HMG-CoA reductase inhibitor examples include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
  • Examples of the thiazolidine derivative include pioglitazone, ciglitazone, rosiglitazone, and troglitazone.
  • combination drugs to be combined with a compound of the present invention includes not only ones discovered to date, but also ones that may be discovered in the future.
  • the compound of the present invention is usually administered systemically or locally, by oral or parenteral administration.
  • oral agents include liquid medicines for internal use (for example, elixirs, syrups, pharmaceutically acceptable water-based agents, suspensions, and emulsions), and solid medicine for internal use (for example, tablets (including sublingual tablets and orally disintegrating tablets), pills, capsules (including hard capsules, soft capsules, gelatin capsules, and microcapsules), powders, granules, and lozenges).
  • parenteral agents examples include liquid medicines (for example, injection agents (e.g., subcutaneous injection agents, intravenous injection agents, intramuscular injection agents, intraperitoneal injection agents, and drip agents), eye drops (for example, aqueous eye drops (e.g., aqueous eye drops, aqueous eye drop suspensions, viscous eye drops, and solubilized eye drops), and nonaqueous eye drops (for example, nonaqueous eye drops and nonaqueous eye drop suspensions)), agents for external use (for example, ointments (e.g., ophthalmic ointments)), and ear drops.
  • injection agents e.g., subcutaneous injection agents, intravenous injection agents, intramuscular injection agents, intraperitoneal injection agents, and drip agents
  • eye drops for example, aqueous eye drops (e.g., aqueous eye drops, aqueous eye drop suspensions, viscous eye drops, and solubilized eye drops), and nonaqueous eye drops (for
  • Liquid medicines for internal use as the oral agent can be produced by, for example, dissolving or suspending an active ingredient in a generally used diluent (for example, purified water, ethanol, or mixture liquid thereof).
  • the liquid medicine may include a wetting agent, a suspension agent, a sweetening agent, a flavoring material, an aromatic substance, a preservative, or a buffer agent.
  • Solid medicines for internal use as the oral agent are formulated by, for example, mixing the active ingredient with, for example, a vehicle (for example, lactose, mannitol, glucose, microcrystalline cellulose, starch), a binder (for example, hydroxypropyl cellulose, polyvinylpyrrolidone, magnesium metasilicate aluminate), a disintegrant (for example, sodium carboxymethylcellulose), a lubricant (for example, magnesium stearate), a stabilizer, a dissolution adjuvant (for example, glutamic acid, aspartic acid), and formulating according to standard methods.
  • a coating agent for example, sugar, gelatin, hydroxypropyl cellulose, hydroxypropyl methyl cellulose phthalate
  • coating of two or more layers may be employed.
  • Agents for external use as parenteral agents are produced by well-known methods or generally used prescriptions.
  • an ointment may be produced by incorporation or melting of an active ingredient into base material.
  • the ointment base material is selected from well-known material or generally used material.
  • a single material or a mixture of two or more of materials are selected from higher fatty acids and higher fatty acid esters (for example, adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipate esters, myristate esters, palmitate esters, stearate esters, oleate esters), waxes (for example, beeswax, spermaceti, ceresin), surfactants (for example, polyoxyethylene alkyl ether phosphate esters), higher alcohols (for example, cetanol, stearyl alcohol, etostearyl alcohol), silicone oils (for example, dimethylpolysiloxane), hydrocarbons (for example, hydrophilic petrolatum, white petrolatum, purified lanolin, liquid paraffin), glycols (for example, ethylene glycol, diethylene glycol, propylene glycol, polyethylene glycol, macrogol), plant oils (for example, castor oil, olive
  • the injection agents as parenteral agents include solutions, suspensions, emulsions and solid injection agents to be dissolved or suspended in a solvent before use.
  • the injection agent is used by, for example, dissolving, suspending or emulsifying an active ingredient in a solvent.
  • the solvent include distilled water for injection, physiological saline, vegetable oils, alcohols such as propylene glycol, polyethylene glycol, ethanol, and mixtures thereof.
  • the injection agent may contain a stabilizer, a dissolution aid (e.g., glutamic acid, aspartic acid, and Polysorbate 80 (registered trademark)), a suspending agent, an emulsifying agent, a soothing agent, a buffer, or a preservative.
  • a dissolution aid e.g., glutamic acid, aspartic acid, and Polysorbate 80 (registered trademark)
  • Such an injection agent is produced by sterilizing at the final step or employing an aseptic process. Furthermore, it is also possible to employ an aseptic solid product such as a freeze-dried product produced and sterilized or dissolved in aseptic distilled water for injection or other solvent before use.
  • the compound of the present invention or combination agents of the compound of the present invention and other agents are usually administered systemically or locally, usually by oral or parenteral administration.
  • the doses to be administered are different depending upon ages, body weights, symptoms, therapeutic effects, administration method, and treatment time.
  • the doses per adult person are generally from 1 ng to 1000 mg per dose, once or several times per day, by oral administration, from 0.1 ng to 100 mg per dose, once or several times per day, by parenteral administration, or continuous administration 1 to 24 hours per day intravenously.
  • the doses to be used vary dependent upon various conditions. Therefore, doses lower than the ranges specified above may be sufficient in some cases, and doses higher than the ranges specified above are needed in some cases.
  • Solvents given in parentheses shown in chromatographic separation and TLC each indicate the eluting solvent or the developing solvent used, and the ratio is expressed in ratio by volume.
  • the description "NH silica” denotes that CHROMATOREX NH TLC PLATE (catalog No.; 3800003) manufactured by FUJI SILYSIA CHEMICAL LTD. is used; and "DNH silica” denotes that CHROMATOREX NH TLC PLATE (catalog No.; 3800403) manufactured by FUJI SILYSIA CHEMICAL LTD. is used;
  • LC-MS/ELSD was carried out in the following conditions: ⁇ Column: Waters ACQUITY C 18 (particle diameter: 1.7 ⁇ 10 -6 ; column length: 30 ⁇ 2.1 mm I.D.); flow rate: 1.0 mL/min; column temperature: 40°C; mobile phase (A): 0.1 % formic acid aqueous solution; mobile phase (B): 0.1 % formic acid-acetonitrile solution; gradient (rate of mobile phase (A) : mobile phase (B)): [0 min] 95:5; [0.1 min] 95:5; [1.2 min] 5:95; [1.4 min] 5:95; [1.41 min] 95:5; [1.5 min] 95:5; detector: UV (PDA), ELSD, MS ⁇
  • Name of the compounds used in this specification are named by using ACD/Name (registered trademark) manufactured by Advanced Chemistry Development Inc., which is a computer program for naming compounds according to the regulation of IUPAC, or named according to the naming method of IUPAC.
  • 1,3-cyclohexanedione (CAS registration No.: 504-02-9 ) (13.25g) was dissolved in N,N-dimethyl formamide (DMF) (200 mL) at room temperature, and tert-butoxy potassium (13.26 g) and ethyl (E)-2-cyano-3-ethoxy-2-propenoate ( CAS registration No.: 94-05-3 ) (20.00 g) were added thereto. The mixture was stirred for 21 hours. The reaction solution was diluted with ethyl acetate, 2 mol/L hydrochloric acid aqueous solution was added thereto, and the mixture was stirred.
  • DMF N,N-dimethyl formamide
  • E ethyl
  • E ethyl-2-cyano-3-ethoxy-2-propenoate
  • the compound (105 mg) produced in Example 4 and O-(7-aza-1-benzotriazolyl)-N,N,N',N'-tetramethyl uronium hexafluorophosphate (HATU) (192 mg) were dissolved in DMF (2 mL) at room temperature, diisopropylethylamine (DIPEA) (0.17 mL) and the compound (100 mg) produced in Example 2 were added thereto, and the mixture was stirred for 21 hours. The solvent was distilled off under reduced pressure.
  • DIPEA diisopropylethylamine
  • Example compounds were obtained by the procedure having the same purpose as in Example 5 using the compound produced in Example 2 and corresponding carboxylic acid derivatives in place of the compound produced in Example 4.
  • Example 1 The title compound having the following physical property values was obtained by the procedure having the same purpose as in Example 1 ⁇ Example ⁇ Example 3 ⁇ Example 4 ⁇ Example 5, using 4-chloro-7-methoxy quinoline ( CAS registration No.: 68500-37-8 ) in place of 4-chloro-6,7-dimethoxy quinoline.
  • Example compounds were obtained by the procedure having the same purpose as in Example 6, using 4-chloro-7-methoxy quinoline or a corresponding quinoline derivative in place of it and the compound produced in Example 4 or a corresponding carboxylic acid derivative in place of it.
  • Example 7 The compound (800 mg) produced in Example 7 was dissolved in dichloromethane (10 mL) at room temperature, trifluoroacetic acid (0.3 mL) was added thereto, and the mixture was stirred at room temperature for six hours.
  • the reaction solution was diluted with ethyl acetate, and saturated sodium bicarbonate water was added to the reaction solution and stirred. Ethyl acetate and water were further added, and the organic layer was extracted. THF and water were added to the water layer, and the organic layer was extracted. The organic layer was collected, washed with a saturated saline solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 4 The compound produced in Example 4 (76 mg) and HATU (154 mg) were dissolved in DMF (1 mL) at room temperature. To the resulting solution, DIPEA (0.14 mL) and the compound produced in Example 8 (80 mg) were added, and the mixture was stirred for 18 hours. The reaction solution was diluted with ethyl acetate, and saturated sodium bicarbonate water was added and stirred. Ethyl acetate and water were further added, and the organic layer was extracted. The organic layer was washed with a saturated saline solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Example compounds were obtained by the procedure having the same purpose as in Example 7 ⁇ Example 8 ⁇ Example 9, using 4-chloro-6,7-dimethoxyquinazoline or a corresponding quinoline derivative in place of it, tert-butyl (5-aminopyridin-2-yl)carbamate or a corresponding amine derivative in place of it, and the compound produced in Example 4.
  • Example 10 The compound produced in Example 10 (42 g) and 1,2-dichlorobenzene (420 mL) were placed in a 1 L-eggplant flask. The mixture was heated and refluxed for 5.5 hours, and left to cool to room temperature. Then, the precipitated powder was collected by filtration. The powder was washed with methanol (84 mL) and dried to obtain the title compound (18 g) having the following physical property values.
  • Example 11 Under argon atmosphere, the compound produced in Example 11 (17 g), toluene (34 mL) and phosphorus oxychloride (10 g) were placed in a 300-mL eggplant flask. The mixture was heated and refluxed for 2.5 hours, left to cool to 70°C, and diluted with ethyl acetate (135 mL). Thereafter, the mixture was left to cool to room temperature, and was neutralized by 2 mol/L sodium hydroxide aqueous solution. The resulting solution was extracted with ethyl acetate, washed with a saturated saline solution and dried over anhydrous sodium sulfate.
  • Example 12 The compound produced in Example 12 (15 g), 6-chloropyridine-3-ol (8.3 g), 4-dimethylaminopyridine (7.5 g), and toluene (75 mL) were placed in a 300-mL eggplant flask. The mixture was heated at 110°C for 6.5 hours, then left to cool to room temperature. Water and ethyl acetate were added thereto, and the resulting solution was separated. The extract solution was washed with a saturated saline solution, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. Then, the resulting residue was dissolved in a small amount of ethyl acetate, and crystallized by adding methanol to the solution.
  • Example 14 The compound produced in Example 14 (800 mg), the compound produced in Example 4 (660 mg), DIPEA (1.2 mL), and DMF (16 mL) were placed in a 30-mL eggplant flask, and finally HATU (1.1 g) was added thereto, followed by stirring at room temperature overnight. After disappearance of the raw material was confirmed, water and ethyl acetate were added, and the resulting solution was separated. The resulting solution was extracted with ethyl acetate, and then washed with water and a saturated saline solution sequentially in this order, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure.
  • Example 15 The compound produced in Example 15 (500 mg), 20% palladium hydroxide-carbon (250 mg), ethyl acetate (18 mL), and methanol (2 mL) were placed in a 200-mL eggplant flask. Under hydrogen atmosphere, the mixture was stirred at room temperature for four hours, followed by filtration through Celite. The filtrate was distilled off under reduced pressure to obtain the title compound (360 mg) having the following physical property values.
  • Example compounds were obtained by the procedure having the same purpose as in Example 16 ⁇ Example 17, using the compound produced in Example 16 and corresponding alcohol derivatives in place of 3-(dimethylamino)-1-propanol.
  • Example 18 Under argon atmosphere, the compound produced in Example 18 (149 mg), tert-butyl carbamate (51 mg), tris(dibenzylideneacetone)dipalladium - chloroform adduct (21 mg), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (35 mg), and cesium carbonate (182 mg) were suspended in 1,4-dioxane (4 mL) in a 50-mL eggplant flask. Thereafter, the suspension was heated to 100°C, stirred for 12 hours, and then left to cool to room temperature. Water was added thereto, followed by extraction with ethyl acetate.
  • Example 19 The compound produced in Example 19 (41 mg) was suspended was suspended in methanol (0.5 mL) in a 50-mL eggplant flask at room temperature. 4 mol/L hydrogen chloride / ethyl acetate solution (1 mL) was added, and the reaction mixture was stirred at room temperature for one hour, and then concentrated to obtain the title compound (35 mg) having the following physical property values.
  • Example compounds were obtained by the procedure having the same purpose as in Example 22 ⁇ Example 23, using 4-chloro-6,7-dimethoxy quinoline or a corresponding quinoline derivative in place of it, 4-aminophenol or a corresponding phenol derivative in place of it.
  • Example compounds were obtained by the procedure having the same purpose as in Example 26, using a carboxylic acid derivative was used in place of the compound produced in Example 4.
  • Example compounds were obtained by the procedure having the same purpose as in Example 27 ⁇ Example 28 ⁇ Example 29, using corresponding quinoline derivatives in place of 4-chloro-6,7-dimethoxyquinazoline, 6-chloropyridine-3-ol, and the compound produced in Example 4 or corresponding carboxylic acid derivatives in place of it.
  • Example 36 Under argon atmosphere, the compound produced in Example 36 (12.0 g) was dissolved in DMA (80 mL) at 50°C. The temperature was returned to room temperature. Then, potassium carbonate (7.35 g) and benzyl bromide (8.75 g) were added thereto. The resulting solution was heated and stirred at 60°C for two hours. The mixture was left to cool to room temperature, and the solvent was concentrated, followed by adding ethyl acetate and water and shaking thereof. Since deposits were precipitated, the deposits were collected by filtration, washed with water and ethyl acetate, and dried under reduced pressure to obtain the title compound (8.0 g) having the following physical property values.
  • Example 11 The title compound having the following physical property values was obtained by the procedure having the same purpose as in Example 11 ⁇ Example 12 ⁇ Example 13 ⁇ Example 14 ⁇ Example 15 ⁇ Example 16 ⁇ Example 17, using the compound produced in Example 37.
  • TLC Rf 0.20 (ethyl acetate, NH silica); 1 H-NMR (CDCl 3 ): ⁇ 2.08-2.19, 2.45-2.64, 3.73, 4.02, 4.27, 6.43, 7.25, 7.43, 7.52-7.65, 8.21, 8.47, 8.49, 9.32, 11.92.
  • Example compounds were obtained by the procedure having the same purpose as in Example 38, using a corresponding compound in place of the compound produced in Example 37.
  • Example compounds were obtained by the procedure having the same purpose as in Example 39 ⁇ Example 40, using a corresponding compound in place of the compound produced in Example 16, 1-bromo-3-methyl-2-butene, and AD-mix- ⁇ or AD-mix- ⁇ .
  • Example compounds were obtained by the procedure having the same purpose as in Example 46, using the compound produced in Example 45, or a compound produced by subjecting the compound produced in Example 43 to the procedure having the same purpose as in Example 44 ⁇ Example 45 using AD-mix- ⁇ in place of AD-mix- ⁇ , and the compound produced in Example 4 or a corresponding carboxylic acid derivative in place of it.
  • Example 48 The title compound having the following physical property values was obtained by the procedure having the same purpose as in Example 48, using a corresponding carboxylic acid derivative in place of the compound produced in Example 47 and the compound produced in Example 2.
  • TLC 0.18 (ethyl acetate);
  • Example 55 The compound produced in Example 55 (120 mg) was dissolved in methanol (2 mL) at room temperature. 2 mol/L sodium hydroxide aqueous solution (0.891 mL) was added to the solution, and the solution was stirred for one hour. 2N hydrochloric acid (0.891 mL) and ethyl acetate were added to the reaction solution, and the solution was separated. The organic layer was washed with a saturated saline solution, then was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (109 mg) having the following physical property values.
  • Example compounds each having the following physical property values were obtained by the procedure having the same purpose as in Example 55 ⁇ Example 56 ⁇ Example 57, using a corresponding derivative in place of the compound produced in Example 54 and the compound produced in Example 2.
  • Example 17 The title compound having the following physical property values was obtained by the procedure having the same purpose as in Example 17, using the compound obtained by subjecting the compound produced in Example 37 to procedure having the same purpose as in Example 11 ⁇ Example 12 ⁇ Example 13 ⁇ Example 14 ⁇ Example 15 ⁇ Example 16, and (S)-(2,2-dimethyl-1,3-dioxolane-4-yl)methanol.
  • TLC Rf 0.60 (ethyl acetate, NH silica); 1 H-NMR (CDCl 3 ): ⁇ 1.42, 1.50, 2.11, 2.60, 4.01, 4.14-4.29, 4.64, 6.44, 7.42, 7.52-7.65, 8.21, 8.47, 8.50, 9.32, 11.92.
  • Example compounds were obtained by the procedure having the same purpose as in Example 59, using the compound produced in Example 58 or a corresponding compound in place of it.
  • Example 11 The title compound having the following physical property values was obtained by the procedure having the same purpose as in Example 11 ⁇ Example 12 ⁇ Example 13 ⁇ Example 14 ⁇ Example 15 ⁇ Example 16, using the compound produced in Example 37.
  • Example 64 The compound produced in Example 64 (1.11 g), potassium acetate (0.66 g), DMF (11 mL), and methanol (11 mL), and, after degassing, [1,1'-bis(diphenylphosphino)ferrocene]palladium(II)dichloride dichloromethane complex (1:1) [PdCl 2 (dppf) 2 CH 2 Cl 2 ] (0.27 g) were placed in a 200-mL eggplant flask. After replacement with carbon monoxide was carried out, stirring at a bath temperature (70°C) was carried out for 17 hours. 1 mol/L hydrochloric acid was added to the reaction solution.
  • LC-MS/ELSD (retention time: 0.75 min); 1 H-NMR (CDCl 3 ): ⁇ 1.97, 2.48, 2.53, 2.56, 3.89, 7.17-7.20, 7.48-7.56.
  • Example 65 The compound produced in Example 65 (1.85 g) and 5 mol/L hydrochloric acid (19 mL) were placed in a 50-mL eggplant flask. The mixture was stirred at a bath temperature (50°C) for 26 hours. Precipitate was removed by filtration, and the filtrate solvent was distilled off under reduced pressure. The resulting residue was washed in a slurry form with methanol and ethyl acetate to obtain the title compound (0.89 g) having the following physical property values.
  • LC-MS/ELSD (retention time: 0.66 min); 1 H-NMR (CD 3 OD): ⁇ 1.97, 2.54, 2.63, 7.29-7.32, 7.54-7.63.
  • An Axl enzyme inhibitory activity was measured by using LanthaScreen (registered trademark) system (Invitrogen) based on the attached instruction.
  • the reagents used are shown below.
  • a 10 mmol/L DMSO solution of the test compound was dispensed into a 96-well plate (Nunc), and, furthermore, a 3-fold dilution series was prepared using DMSO.
  • 5 ⁇ L each of the reaction buffer solution containing DMSO was added to a Blank group and a medium group, and 5 ⁇ L of the test substance solution was added to the test substance group, respectively.
  • 10 ⁇ L/well of the reaction buffer solution was added to the Blank group, and 10 ⁇ L/well each of the enzyme solution was added to the medium group and the test compound group, followed by stirring at room temperature for 10 min.
  • IC50 values 50% inhibition rate (IC50 values) of the test compound were calculated from the inhibition curve based on the inhibition rate of the test compounds in each concentration.
  • IC50 values of the compound of, for example, Examples 5, 5(1), 5(6), 17(2), and 23(2) were 0.0022 ⁇ M, 0.0056 ⁇ M, 0.0043 ⁇ M, 0.0044 ⁇ M, and 0.0011 ⁇ M, respectively.
  • DMSO solution of the test compound was dispensed into a 96-well plate, and a 3-fold dilution series was prepared using DMSO.
  • DMSO solutions of test compounds, having various concentrations, were further 500-fold diluted with a RPMI1640 medium (containing 10% HI-FBS, 1% penicillin) and a diluted solution of the test compound having 500-fold concentration with respect to the final concentration was prepared.
  • each well of the 96-well plate for measurement 50 ⁇ L each of the RPMI medium was added to the Blank group, and 50 ⁇ L each of the cell suspension to the medium group and the test compound group, respectively, and the groups were stood still at 37°C at 5%CO 2 for 48 hours. After standing still, Relative Light Unit (RLU) was measured by using CELLTITER-GLO (registered trademark) LUMINESCENT CELL VIABILITY ASSAY (Promega). The measurement was carried out according to the attached instruction. To each well, 100 ⁇ L each of light-emitting solution was added.
  • RLU Relative Light Unit
  • a value of 50% inhibition rate (IC50 value) of the test compound was calculated from the inhibition curve based on the inhibition rate in each concentration of the test compound.
  • IC50 values of the compounds of, for example, Examples 5, 5(1), 5(6), 17(2), and 23(2) were 0.0007 ⁇ M, 0.0008 ⁇ M, 0.0078 ⁇ M, 0.0012 ⁇ M, and 0.0012 ⁇ M, respectively.
  • IC50 values of the comparative compounds A and B were 0.62 ⁇ M and > 10 ⁇ M, respectively.
  • KDR is kinase also referred to as vascular endothelial growth factor receptor 2 (VEGF Receptor 2). It is known that inhibition of KDR may cause a side effect of increasing blood pressure ( Hypertension, vol. 39, p. 1095-1100, 2002 ). Therefore, it was suggested that the compounds of the present invention were excellent compounds capable of avoiding the side effect, which was a problem in comparative compounds, for example, hypertension. Furthermore, it has been also suggested that the other three types of kinases (DDR1, FLT4, and ROS) might cause side effect to be avoided, from the phenotype of the KO mouse or transgenic mouse. It became apparent that the compound of the present invention has excellent selectivity to such specific kinases and therefore capable of avoiding side effect.
  • DDR1, FLT4, and ROS three types of kinases
  • the reaction was carried out in a 384-well plate.
  • CYP2C8 quercetin
  • a solution which had been adjusted with DMSO to have 300 times higher concentration than the final concentration (CYP2C8: 22.5 and 225 ⁇ mol/L) and been 75-fold diluted with purified water containing 2.7% acetonitrile, was prepared (CYP2C8: 0.3 and 3 ⁇ mol/L).
  • the test compounds were prepared to have a concentration of 0.3 and 3 mol/L with DMSO, and then 75-fold diluted with purified water containing 2.7% acetonitrile to be 4 and 40 ⁇ mol/L.
  • a reaction mixture solution was prepared by addition of a potassium phosphate buffer (pH 7.4), magnesium chloride (5 mol/L), substrate (CYP2C8: Luciferin-ME, 150 ⁇ mol/L), and E. coli-expressed liver microsome CYP2C8 (Cypex, 30 pmol/L) (the numerical values are final concentrations).
  • the reaction was started by addition of 8 ⁇ L of this reaction mixture, 4 ⁇ L each of the test compound and the positive control solution which had been prepared as described above, and 4 ⁇ L of NADPH production system solution (5.2 mM NADP, 13.2 mM glucose-6-phosphate, 1.6 U/mL glucose-6-phosphate dehydrogenase) and incubation was carried out at 37°C for 30 min. Thereafter, 16 ⁇ L of luciferase solution was added to stop the reaction and to allow luciferin to emit light, and the luminescence intensity of the reaction solution was measured.
  • NADPH production system solution 5.2 mM NADP, 13.2 mM glucose-6-phosphate, 1.6 U/mL glucose-6-phosphate dehydrogenase
  • the inhibition rate is a reduction rate (inhibition rate) of the luminescence intensity when compared with the control in which the reaction was carried out by the addition of DMSO in place of the test compound solution.
  • the IC50 value was defined to be ⁇ 1 ⁇ M when the inhibition rate at 1 ⁇ mol/L was not less than 50%; and > 10 ⁇ M when the inhibition rate at 10 ⁇ mol/L was not more than 50%.
  • the IC50 values of the comparative compounds and compounds of the present invention were measured using the measurement method described above.
  • the IC50 value of CYP2C8 was 2.6 ⁇ M for the comparative compound E (Example 133 described in Patent Literature 4).
  • the IC50 values of CYP2C8 were > 10 ⁇ M in the compounds of, for example, Examples 5, 5(1), 17(2), and 23(2). Therefore, it was shown that the compound of the present invention had less CYP inhibition effect with respect to the comparative compound.
  • the components indicated below were mixed by a standard method, followed by making the mixture into tablets to obtain 10,000 tablets each containing 10 mg of active ingredient.
  • a compound of the present invention has a strong Axl inhibitory activity, and therefore, is useful for treatment for Axl-related diseases, for example, cancer, kidney diseases, immune system diseases, and circulatory system diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (14)

  1. Verbindung, dargestellt durch die allgemeine Formel (1):
    Figure imgb0068
    wobei R1 (1) eine C1-8-Alkylgruppe, die wahlweise mit einem bis fünf R11 substituiert ist, (2) einen C3-7-Kohlenstoffring, der wahlweise mit einem bis fünf R12 substituiert ist, oder (3) einen 4- bis 7-gliedrigen Heterocyclus, der wahlweise mit einem bis fünf R13 substituiert ist, darstellt, wobei, wenn die durch R1 dargestellte C1-8-Alkylgruppe eine verzweigte Alkylgruppe ist, die von demselben Kohlenstoffatom verzweigte C1-3-Alkylgruppe zusammen mit dem daran gebundenen Kohlenstoffatom wahlweise einen gesättigten C3-7-Kohlenstoffring bildet,
    R2 (1) eine C1-4-Alkylgruppe, (2) ein Halogenatom, (3) eine C1-4-Halogenalkylgruppe, (4) eine Oxogruppe, (5) eine -OR21-Gruppe oder (6) eine =NR22-Gruppe darstellt,
    R3 (1) eine C1-4-Alkylgruppe, (2) ein Halogenatom oder (3) eine C1-4-Halogenalkylgruppe darstellt,
    R4 (1) eine C1-4-Alkoxygruppe, (2) eine C1-4-Haloalkylgruppe, (3) eine -OR41-Gruppe, (4) eine C1-4-Alkylgruppe, (5) eine C2-4-Alkenyloxygruppe oder (6) eine C2-4-Alkinyloxygruppe darstellt,
    R5 (1) ein Wasserstoffatom, (2) eine C1-4-Alkylgruppe, (3) ein Halogenatom, (4) eine C1-4-Halogenalkylgruppe oder (5) eine -OR21-Gruppe darstellt,
    R11 (1) eine -OR101-Gruppe, (2) eine SO2R102-Gruppe, (3) eine NR103R104-Gruppe oder (4) einen C3-7-Kohlenstoffring, der wahlweise mit einem bis drei Halogenatomen substituiert ist, darstellt,
    R12 (1) eine C1-8-Alkylgruppe, die wahlweise mit einer Hydroxylgruppe substituiert ist, oder (2) ein Halogenatom darstellt,
    R13 (1) eine C1-8-Alkylgruppe, die wahlweise mit einer Hydroxylgruppe substituiert ist, oder (2) ein Halogenatom darstellt,
    R21 (1) ein Wasserstoffatom oder (2) eine C1-4-Alkylgruppe darstellt,
    R22 (1) eine Hydroxylgruppe oder (2) eine C1-4-Alkoxygruppe darstellt,
    R41 darstellt: (1) ein Wasserstoffatom, (2) eine C1-8-Alkylgruppe, die mit einem bis zwei Substituenten substituiert ist, die aus der Gruppe ausgewählt sind, die aus (a) einer 5- bis 7-gliedrigen cyclischen Gruppe, die wahlweise mit einem bis zwei Substituenten substituiert ist, die aus der Gruppe ausgewählt sind, die aus (i) einer C1-4-Alkylgruppe, (ii) einer C1-4-Halogenalkylgruppe und (iii) einem Halogenatom besteht, (b) NR401R402, (c) einer Hydroxylgruppe und (d) einer SO2R403-Gruppe besteht, (3) eine C2-8-Alkenylgruppe, die mit ein bis zwei Substituenten substituiert ist, die aus der Gruppe ausgewählt sind, die aus (a) einer 5- bis 7-gliedrigen cyclischen Gruppe, die wahlweise mit ein bis zwei Substituenten substituiert ist, die aus der Gruppe ausgewählt sind, die aus (i) einer C1-4-Alkylgruppe, (ii) einer C1-4-Halogenalkylgruppe und (iii) einem Halogenatom besteht, (b) NR401R402, (c) einer Hydroxylgruppe und (d) einer SO2R403-Gruppe besteht, oder (4) eine C2-8-Alkinylgruppe, die mit einem bis zwei Substituenten substituiert ist, die aus der Gruppe ausgewählt sind, die aus (a) einer 5- bis 7-gliedrigen cyclischen Gruppe, die wahlweise mit einem bis zwei Substituenten substituiert ist, die aus der Gruppe ausgewählt sind, die aus (i) einer C1-4-Alkylgruppe, (ii) einer C1-4-Halogenalkylgruppe und (iii) einem Halogenatom besteht, (b) NR401R402, (c) einer Hydroxylgruppe und (d) einer SO2R403-Gruppe besteht,
    R101 (1) ein Wasserstoffatom oder (2) eine C1-4-Alkylgruppe darstellt,
    R102 (1) ein Wasserstoffatom oder (2) eine C1-4-Alkylgruppe darstellt,
    R103 und R104 jeweils unabhängig voneinander (1) ein Wasserstoffatom oder (2) eine C1-4-Alkylgruppe darstellen,
    R401 und R402 jeweils unabhängig voneinander (1) ein Wasserstoffatom oder (2) eine C1-4-Alkylgruppe darstellen,
    R403 (1) ein Wasserstoffatom oder (2) eine C1-4-Alkylgruppe darstellt,
    A (1) CH oder (2) ein Stickstoffatom darstellt,
    L (1) -O-, (2) -NH-, (3) -C(O)-, (4) -CR6R7-, (5) -S-, (6) -S(O)- oder (7) -S(O)2- darstellt,
    R6 und R7 jeweils unabhängig voneinander (1) ein Wasserstoffatom, (2) ein Halogenatom, (3) eine C1-4-Alkylgruppe, (4) eine Hydroxylgruppe oder (5) NH2 darstellen,
    Ring1 Benzol oder Pyridin darstellt,
    ------ eine Einfachbindung oder eine Doppelbindung darstellt,
    m eine ganze Zahl von 0 bis 5 ist,
    n eine ganze Zahl von 0 bis 5 ist,
    m eine ganze Zahl von 0 bis 5 ist,
    p eine ganze Zahl von 0 bis 2 ist,
    q eine ganze Zahl von 0 bis 5 ist,
    wenn m zwei oder mehr ist, eine Vielzahl von R2 gleich oder verschieden voneinander sein kann, und wenn zwei von R2 eine C1-3-Alkylgruppe darstellen und sich am selben Kohlenstoffatom befinden, die R2 zusammen mit einem daran gebundenen Kohlenstoffatom einen gesättigten C3-7-Kohlenstoffring bilden können,
    wenn n 2 oder mehr ist, eine Vielzahl von R3 gleich oder verschieden voneinander sein kann und
    wenn q 2 oder mehr ist, eine Vielzahl von R4 gleich oder verschieden voneinander sein kann,
    ein Salz davon, ein Solvat davon oder ein N-Oxid davon.
  2. Verbindung gemäß Anspruch 1, wobei m eins oder mehr ist und einer von R2 unbedingt eine Oxogruppe ist.
  3. Verbindung gemäß Anspruch 1 oder 2, wobei L (1) -O-, (2) -NH- oder (3) -C(O)-ist.
  4. Verbindung gemäß Anspruch 1, die durch die allgemeine Formel (I-1) dargestellt wird:
    Figure imgb0069
    wobei R2-1 (1) eine C1-4-Alkylgruppe, (2) ein Halogenatom, (3) eine C1-4-Halogenalkylgruppe, (4) eine -OR21-Gruppe oder (5) eine =NR22-Gruppe darstellt,
    m-1 eine ganze Zahl von 0 bis 4 ist,
    L1 (1) -O-, (2) -NH- oder (3) -C(O)- ist,
    Ring1-1 Benzol oder Pyridin darstellt,
    wenn m-1 2 oder mehr ist, eine Vielzahl von R2-1 gleich oder verschieden voneinander sein kann, und wenn zwei von R2-1 eine C1-3-Alkylgruppe darstellen und sich am selben Kohlenstoffatom befinden, die R2-1 zusammen mit einem daran gebundenen Kohlenstoffatom einen gesättigten C3-7-Kohlenstoffring bilden können,
    und die anderen Symbole die gleichen Bedeutungen wie in Anspruch 1 definiert haben.
  5. Verbindung gemäß einem der Ansprüche 1 bis 4, welche
    (2) N-{5-[(6,7-Dimethoxy-4-chinolinyl)oxy]-2-pyridinyl}-7,7-dimethyl-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (3) N-{5-[(6,7-Dimethoxy-4-chinolinyl)oxy]-2-pyridinyl}-1-(2,2-dimethylpropyl)-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (4) N-[5-({7-[3-(4-Morpholinyl)propoxy]-4-chinolinyl}oxy)-2-pyridinyl]-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (5) (N-{4-[(6,7-Dimethoxy-4-chinolinyl)oxy]-3-fluorphenyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (6) N-{4-[(6,7-Dimethoxy-4-chinolinyl)oxy]phenyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (7) N-{5-[(6,7-Dimethoxy-4-chinolinyl)oxy]-2-pyridinyl}-1-(4-fluorphenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (8) N-{5-[(6,7-Dimethoxy-4-chinolinyl)oxy]-2-pyridinyl}-1-(3-fluorphenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (9) N-{5-[(6,7-Dimethoxy-4-chinolinyl)oxy]-2-pyridinyl}-1-(2-fluorphenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (10) N-{5-[(6,7-Dimethoxy-4-chinazolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (11) N-{5-[(6,7-Dimethoxy-4-chinazolinyl)oxy]-2-pyridinyl}-1-(4-fluorphenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (12) N-{5-[(6,7-Dimethoxy-4-chinolinyl)oxy]-2-pyridinyl}-1-[(2S)-1-hydroxy-3-methyl-2-butanyl]-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (13) N-{4-[(6,7-Dimethoxy-4-chinolinyl)oxy]-3-fluorphenyl}-1-(3-fluorphenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (14) N-{5-[(6,7-Dimethoxy-4-chinolinyl)oxy]-2-pyridinyl}-6,6-dimethyl-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (15) N-[5-({6-Methoxy-7-[3-(4-morpholinyl)propoxy]-4-chinolinyl}oxy)-2-pyridinyl]-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid,
    (16) N-(5-{[7-(3-Hydroxy-3-methylbutoxy)-6-methoxy-4-chinolinyl]oxy}-2-pyridinyl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid oder
    (17) N-[5-({6-Methoxy-7-[3-(1-pyrrolidinyl)propoxy]-4-chinolinyl}oxy)-2-pyridinyl]-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-chinolincarboxamid ist.
  6. Pharmazeutische Zusammensetzung, enthaltend eine Verbindung, welche durch die allgemeine Formel (I) wie in Anspruch 1 definiert dargestellt wird, ein Salz davon, ein Solvat davon oder ein N-Oxid davon.
  7. Pharmazeutische Zusammensetzung gemäß Anspruch 6, bei der es sich um einen Axl-Inhibitor handelt.
  8. Pharmazeutische Zusammensetzung gemäß Anspruch 6, die ein Mittel zum Verhindern und/oder Behandeln einer mit Axl in Beziehung stehenden Krankheit ist.
  9. Pharmazeutische Zusammensetzung gemäß Anspruch 8, wobei die mit Axl in Beziehung stehende Krankheit Krebs, eine Nierenerkrankung, eine Erkrankung des Immunsystems oder eine Erkrankung des Kreislaufsystems einschließt.
  10. Pharmazeutische Zusammensetzung gemäß Anspruch 9, wobei der Krebs akute myeloische Leukämie, chronische myeloische Leukämie, akute lymphatische Leukämie, Melanom, Brustkrebs, Bauchspeicheldrüsenkrebs, Gliom, Ösophagus-Adenokarzinom, Dickdarmkrebs, Nierenzellkarzinom, Schilddrüsenkrebs, nicht kleinzelliger Lungenkrebs, Prostatakrebs, Magenkrebs, Leberkrebs, malignes Melanom der mittleren Augenhaut, Eierstockkrebs, Endometriumkrebs, Lymphom, Kopf- und Halskrebs oder Sarkom ist.
  11. Pharmazeutische Zusammensetzung gemäß Anspruch 6, die ein Metastasen unterdrückendes Mittel für Krebszellen ist.
  12. Verbindung, welche durch die allgemeine Formel (I) gemäß Anspruch 1 dargestellt wird, ein Salz davon, ein Solvat davon oder ein N-Oxid davon zur Verwendung beim Verhindern und/oder Behandeln einer mit Axl in Beziehung stehenden Krankheit.
  13. Verbindung zur Verwendung gemäß Anspruch 12, wobei die mit Axl in Beziehung stehende Krankheit Krebs, eine Nierenerkrankung, eine Erkrankung des Immunsystems oder eine Erkrankung des Kreislaufsystems einschließt.
  14. Verbindung zur Verwendung gemäß Anspruch 13, wobei der Krebs akute myeloische Leukämie, chronische myeloische Leukämie, akute lymphatische Leukämie, Melanom, Brustkrebs, Bauchspeicheldrüsenkrebs, Gliom, Ösophagus-Adenokarzinom, Dickdarmkrebs, Nierenzellkarzinom, Schilddrüsenkrebs, nicht kleinzelliger Lungenkrebs, Prostatakrebs, Magenkrebs, Leberkrebs, malignes Melanom der mittleren Augenhaut, Eierstockkrebs, Endometriumkrebs, Lymphom, Kopf- und Halskrebs oder Sarkom ist.
EP18185739.2A 2013-07-24 2014-07-23 Chinolinderivat Active EP3415501B9 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013153350 2013-07-24
EP14828976.2A EP3026045B1 (de) 2013-07-24 2014-07-23 Chinolinderivat
PCT/JP2014/069419 WO2015012298A1 (ja) 2013-07-24 2014-07-23 キノリン誘導体

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP14828976.2A Division-Into EP3026045B1 (de) 2013-07-24 2014-07-23 Chinolinderivat
EP14828976.2A Division EP3026045B1 (de) 2013-07-24 2014-07-23 Chinolinderivat

Publications (3)

Publication Number Publication Date
EP3415501A1 EP3415501A1 (de) 2018-12-19
EP3415501B1 true EP3415501B1 (de) 2020-04-08
EP3415501B9 EP3415501B9 (de) 2020-12-02

Family

ID=52393331

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14828976.2A Active EP3026045B1 (de) 2013-07-24 2014-07-23 Chinolinderivat
EP18185739.2A Active EP3415501B9 (de) 2013-07-24 2014-07-23 Chinolinderivat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP14828976.2A Active EP3026045B1 (de) 2013-07-24 2014-07-23 Chinolinderivat

Country Status (23)

Country Link
US (6) US9573935B2 (de)
EP (2) EP3026045B1 (de)
JP (2) JP6213564B2 (de)
KR (1) KR102251609B1 (de)
CN (1) CN105408312B (de)
AU (1) AU2014294109B2 (de)
BR (1) BR112016001515B1 (de)
CA (1) CA2918888C (de)
DK (1) DK3026045T3 (de)
ES (2) ES2798150T3 (de)
HK (1) HK1219735A1 (de)
HU (1) HUE040238T2 (de)
IL (1) IL243743B (de)
MX (1) MX365377B (de)
MY (1) MY191433A (de)
PH (1) PH12016500150A1 (de)
PL (1) PL3026045T3 (de)
PT (1) PT3026045T (de)
RU (1) RU2666895C2 (de)
SG (1) SG11201600533XA (de)
TW (1) TWI649308B (de)
WO (1) WO2015012298A1 (de)
ZA (1) ZA201600514B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
US20150299219A1 (en) 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
ES2749726T3 (es) * 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
WO2016183071A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Hetero-tricyclic compounds and their use for the treatment of cancer
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
EP3372231B1 (de) 2015-11-04 2021-09-15 Astellas Pharma Inc. Pharmazeutische zusammensetzung zum zwecke der krebsimmuntherapie und/oder immunstimulation mit heterozyklischer diamino-carboxamid-verbindung als wirkstoff
ES2896079T3 (es) 2016-02-26 2022-02-23 Ono Pharmaceutical Co Fármaco para la terapia del cáncer, caracterizado por la administración de la combinación entre un inhibidor de Axl y un inhibidor del punto de control inmunitario
PT3436461T (pt) 2016-03-28 2024-01-23 Incyte Corp Compostos de pirrolotriazina como inibidores de tam
WO2017168448A1 (en) 2016-03-30 2017-10-05 Council Of Scientific & Industrial Research Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity
CN108250200A (zh) * 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
RU2019123279A (ru) * 2017-01-26 2021-02-26 Оно Фармасьютикал Ко., Лтд. Этан-сульфонатная соль производного хинолина
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JP7156287B2 (ja) * 2017-08-23 2022-10-19 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含むがん治療剤
JP2020535168A (ja) 2017-09-27 2020-12-03 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍ阻害剤として有用なピロロトリアジン誘導体の塩
WO2019074116A1 (ja) 2017-10-13 2019-04-18 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
JP2021525755A (ja) * 2018-06-01 2021-09-27 ライジェル ファーマシューティカルズ， インコーポレイテッド チロシンキナーゼ阻害剤として有用なキノリン誘導体
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
CN109232416B (zh) * 2018-10-24 2021-09-24 福州大学 一种合成4-三氟甲基-2-吡喃酮/吡啶酮化合物的方法
EP3942045A1 (de) 2019-03-21 2022-01-26 Onxeo Dbait-molekül in kombination mit einem kinaseinhibitor zur behandlung von krebs
CN110078675B (zh) * 2019-04-25 2022-09-23 郑州大学 4-芳基喹唑啉类化合物及其制备方法
WO2021062245A1 (en) * 2019-09-26 2021-04-01 Exelixis, Inc. Pyridone compounds and methods of use in the modulation of a protein kinase
EP4054579A1 (de) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von krebsarten, die resistenz gegen kinase-inhibitoren erworben haben
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US20230151003A1 (en) * 2020-02-24 2023-05-18 Exelixis, Inc. Compounds and methods of use
CN116390729A (zh) * 2020-05-18 2023-07-04 伟迈可生物有限公司 用于预防或治疗与ron突变相关的非小细胞肺癌的药物组合物及其使用方法
US20230242521A1 (en) * 2020-05-18 2023-08-03 Wellmarker Bio Co., Ltd. Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same
CN115916210A (zh) * 2020-05-18 2023-04-04 伟迈可生物有限公司 用于预防或治疗与ron突变相关的小细胞肺癌的药物组合物及其使用方法
CA3211063A1 (en) * 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
TW202304908A (zh) * 2021-04-14 2023-02-01 日商衛材R&D企管股份有限公司 四氫吡啶并嘧啶化合物
WO2022237843A1 (zh) * 2021-05-12 2022-11-17 微境生物医药科技(上海)有限公司 Axl抑制剂
AR126963A1 (es) * 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR79603B (de) * 1982-07-24 1984-10-31 Pfizer
RU2240313C2 (ru) * 1999-10-25 2004-11-20 Эктив Байотек Аб Лекарственные средства для лечения злокачественных опухолей
CA2396079A1 (en) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
EP2023926B1 (de) 2006-05-19 2011-10-12 Bayer Pharma Aktiengesellschaft Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
WO2007146824A2 (en) * 2006-06-08 2007-12-21 Array Biopharma Inc. Quinoline compounds and methods of use
US9206130B2 (en) 2008-04-16 2015-12-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as AXL kinase inhibitors
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
JP5699075B2 (ja) 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
AU2009300328A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
JP2010178651A (ja) 2009-02-04 2010-08-19 Eisai R & D Management Co Ltd Ｈｇｆｒ阻害物質の作用検定方法
WO2012011548A1 (ja) 2010-07-23 2012-01-26 国立大学法人 東京大学 含窒素複素環誘導体
EP2423208A1 (de) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmazeutisch aktive Zusammensetzungen als Axl-Hemmer
DK2835131T3 (en) 2010-12-14 2017-12-04 Electrophoretics Ltd Casein kinase 1 delta inhibitors (CK1 delta)
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
EP2780338B1 (de) 2011-11-14 2016-11-09 Ignyta, Inc. Uracilderivate als axl- und c-met-kinaseinhibitoren
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US9573935B2 (en) 2017-02-21
EP3026045B1 (de) 2018-10-03
ZA201600514B (en) 2019-09-25
PT3026045T (pt) 2018-11-20
SG11201600533XA (en) 2016-02-26
HK1219735A1 (zh) 2017-04-13
ES2694513T3 (es) 2018-12-21
CA2918888C (en) 2022-05-17
IL243743A0 (en) 2016-04-21
EP3415501B9 (de) 2020-12-02
US20170088542A1 (en) 2017-03-30
DK3026045T3 (da) 2019-01-02
ES2798150T3 (es) 2020-12-09
RU2016102036A3 (de) 2018-04-25
BR112016001515A2 (de) 2017-07-25
US20190135785A1 (en) 2019-05-09
EP3026045A4 (de) 2017-01-04
MY191433A (en) 2022-06-27
CN105408312A (zh) 2016-03-16
JPWO2015012298A1 (ja) 2017-03-02
AU2014294109B2 (en) 2018-02-01
PH12016500150B1 (en) 2016-04-18
PH12016500150A1 (en) 2016-04-18
HUE040238T2 (hu) 2019-02-28
JP6436205B2 (ja) 2018-12-12
BR112016001515B1 (pt) 2022-09-13
PL3026045T3 (pl) 2019-02-28
CA2918888A1 (en) 2015-01-29
NZ716244A (en) 2020-10-30
MX2016000989A (es) 2016-05-16
US20180258072A1 (en) 2018-09-13
KR102251609B1 (ko) 2021-05-13
WO2015012298A1 (ja) 2015-01-29
RU2666895C2 (ru) 2018-09-13
US9994549B2 (en) 2018-06-12
TW201542528A (zh) 2015-11-16
JP2018024691A (ja) 2018-02-15
US10501442B2 (en) 2019-12-10
US20200392110A1 (en) 2020-12-17
EP3415501A1 (de) 2018-12-19
CN105408312B (zh) 2018-09-25
MX365377B (es) 2019-05-31
RU2016102036A (ru) 2017-08-29
KR20160033707A (ko) 2016-03-28
TWI649308B (zh) 2019-02-01
US10208022B2 (en) 2019-02-19
IL243743B (en) 2019-05-30
US10676462B2 (en) 2020-06-09
US20160168121A1 (en) 2016-06-16
JP6213564B2 (ja) 2017-10-18
US20200002313A1 (en) 2020-01-02
AU2014294109A1 (en) 2016-02-11
EP3026045A1 (de) 2016-06-01

Similar Documents

Publication Publication Date Title
US10676462B2 (en) Quinoline derivative
EP3239147B9 (de) Chinolinderivat
EP3067356B1 (de) Pyrrolopyrimidinderivate
NZ716244B2 (en) Quinoline derivative

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180726

AC Divisional application: reference to earlier application

Ref document number: 3026045

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20191008BHEP

Ipc: A61P 35/00 20060101ALI20191008BHEP

Ipc: A61P 35/04 20060101ALI20191008BHEP

Ipc: A61P 25/02 20060101ALI20191008BHEP

Ipc: C07D 401/12 20060101ALI20191008BHEP

Ipc: A61P 37/02 20060101ALI20191008BHEP

Ipc: C07D 401/14 20060101ALI20191008BHEP

Ipc: C07D 215/54 20060101AFI20191008BHEP

Ipc: A61P 35/02 20060101ALI20191008BHEP

Ipc: A61K 31/4709 20060101ALI20191008BHEP

Ipc: A61P 9/00 20060101ALI20191008BHEP

Ipc: A61P 13/12 20060101ALI20191008BHEP

Ipc: A61K 31/5377 20060101ALI20191008BHEP

INTG Intention to grant announced

Effective date: 20191025

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001093

Country of ref document: HK

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 3026045

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1254207

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014063692

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200408

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200709

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200808

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200817

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG B9

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1254207

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2798150

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20201209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014063692

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

26N No opposition filed

Effective date: 20210112

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200731

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200723

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200731

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230509

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230612

Year of fee payment: 10

Ref country code: FR

Payment date: 20230620

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230601

Year of fee payment: 10

Ref country code: ES

Payment date: 20230801

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230531

Year of fee payment: 10